| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Molecular Neurobiology Branch, NIDA-IRP, National Institutes of Health, Baltimore, Maryland 21224, USA
1Correspondence: Molecular Neurobiology, Rm. 302, 5500 Nathan Shock Dr., Baltimore, MD 21224, USA. E-mail guhl{at}intra.nida.nih.gov
Monoamine compartmentalization in monoaminergic neurons uses serial action of the plasma membrane and vesicular monoamine (VAMT2) transporters. We can now define the sequences of the genes encoding these transporters in mice and humans, examine influences of deletions of this gene and alteration in its expression levels in transgenic mice, and identify sequence polymorphisms in the human VMAT2 gene. Examination of VMAT2 variants can provide potential insights into roles for allelic variants at these loci in variant drug responses and in diseases linked to monoaminergic systems, including substance abuse and Parkinson’s disease.—Uhl, G. R., Li, S., Takahashi, N., Itokawa, K., Lin, Z., Hazama, M., Sora, I. The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins
Key Words: VMAT2 • serotonin • histamine • dopamine • norepinephrine • synaptic vesicle • Parkinsonism • MPTP
This article has been cited by other articles:
|
|
 |
|
  T. D. Gallardo, G. B. John, L. Shirley, C. M. Contreras, E. A. Akbay, J. M. Haynie, S. E. Ward, M. J. Shidler, and D. H. Castrillon Genomewide Discovery and Classification of Candidate Ovarian Fertility Genes in the Mouse Genetics, September 1, 2007; 177(1): 179 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Anlauf, M. K.-H. Schafer, T. Schwark, N. von Wurmb-Schwark, V. Brand, B. Sipos, H.-P. Horny, R. Parwaresch, W. Hartschuh, L. E. Eiden, et al. Vesicular Monoamine Transporter 2 (VMAT2) Expression in Hematopoietic Cells and in Patients with Systemic Mastocytosis J. Histochem. Cytochem., February 1, 2006; 54(2): 201 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Glatt, A. D. Wahner, D. J. White, A. Ruiz-Linares, and B. Ritz Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women Hum. Mol. Genet., January 15, 2006; 15(2): 299 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Miller, C. D. Verrico, A. Jassen, M. Konar, H. Yang, H. Panas, M. Bahn, R. Johnson, and B. K. Madras Primate Trace Amine Receptor 1 Modulation by the Dopamine Transporter J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 983 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. SIDHU, C. WERSINGER, C. E-H. MOUSSA, and P. VERNIER The Role of {alpha}-Synuclein in Both Neuroprotection and Neurodegeneration Ann. N.Y. Acad. Sci., December 1, 2004; 1035(1): 250 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Numis, E. L. Unger, D. L. Sheridan, A. C. Chisnell, and A. M. Andrews The Role of Membrane and Vesicular Monoamine Transporters in the Neurotoxic and Hypothermic Effects of 1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH2-MPTP) Mol. Pharmacol., September 1, 2004; 66(3): 718 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. SIDHU, C. WERSINGER, and P. VERNIER Does {alpha}-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J, April 1, 2004; 18(6): 637 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. EIDEN The vesicular neurotransmitter transporters: current perspectives and future prospects FASEB J, December 1, 2000; 14(15): 2396 - 2400. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
